In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO and C-suite leaders from the CDMO ecosystem, exploring two simple questions that reveal what’s really happening inside the building:
What’s the biggest internal business challenge for the year ahead?
And what’s the biggest opportunity inside their business in 2026?
Your host, Raman Sehgal, brings together a punchy set of operator insights spanning commercial readiness, capacity decisions, flawless execution, commercial excellence, and the shift toward deeper partnerships and integrated models.
Show features insights from:
- Ankit Gupta, CEO, InstaPill
- Nick Fortin, CEO, Codis
- Eric Edwards, MD, PhD, CEO, Phlow USA
- Jason Anderson, CEO, ensera
- Dirk T. Lange, CEO, Pyramid Pharma Services
- Philip Macnabb, CEO, Curia
- Matthew Bio, CSO, Cambrex and President, Snapdragon Chemistry
- Bruce Thompson, CTO, Kincell Bio
- Bill Vincent, Biotech Entrepreneur, CEO and Board Member
- Derek Hennecke, Founder, Investor and Board Member
- Stephen Dilly, CEO, Sonoma Biotherapeutics
- Elisabeth Stampa, CEO, Medichem
- Christiane Bardroff, COO Leader
- Kaan-Fabian Kekec, Partner, Simon-Kucher Healthcare and Life Sciences
- Ian Tzeng, Managing Director, L.E.K. Consulting
- Adam Siebert, Managing Director, L.E.K. Consulting
- J.D. Mowery, President, CDMO Division, Bora Pharmaceuticals
- Jon Alberdi, CEO, Vivebiotech
- Peter Belden, President, US, Tjoapack
Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
